Literature DB >> 10528127

The GABA(B) receptor antagonist CGP36742 improves learned helplessness in rats.

Y Nakagawa1, A Sasaki, T Takashima.   

Abstract

Effects of 3-aminopropyl-n-butyl-phosphinic acid (CGP36742), a GABA(B) receptor antagonist, in the learned helplessness paradigm were examined in rats in comparison with those of imipramine and endo-8-methyl-8-azabicyclo[3,2,1]oct-3-ol indol-3-yl-carboxylate hydrochloride (ICS205-930). Rats were treated with CGP36742, imipramine or ICS205-930 for 14 days. On day 14, the rats were subjected to 90 inescapable shocks. On day 15, the rats received the 40-trial escape test. The inescapable shocks increased escape failures in the escape test. CGP36742, imipramine and ICS205-930 dose-dependently improved the escape failures induced by the inescapable shocks. Baclofen attenuated the escape failures-improving effect of CGP36742, imipramine and ICS205-930. Although the action of imipramine and ICS205-930 was attenuated by 1-(m-chlorophenyl)-biguanide (mCPBG), mCPBG failed to influence the CGP36742 action. Therefore, it is suggested that CGP36742 may have an antidepressant profile and that the mechanisms of CGP36742 in antidepressant action may be different from those of imipramine and ICS205-930.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10528127     DOI: 10.1016/s0014-2999(99)00567-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  14 in total

Review 1.  Is the GABA B heterodimer a good drug target?

Authors:  Fiona H Marshall
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

2.  Both GABA(B) receptor activation and blockade exacerbated anhedonic aspects of nicotine withdrawal in rats.

Authors:  Styliani Vlachou; Neil E Paterson; Sebastien Guery; Klemens Kaupmann; Wolfgang Froestl; Deboshri Banerjee; M G Finn; Athina Markou
Journal:  Eur J Pharmacol       Date:  2011-01-22       Impact factor: 4.432

3.  Blunted 5-HT1A receptor-mediated responses and antidepressant-like behavior in mice lacking the GABAB1a but not GABAB1b subunit isoforms.

Authors:  Laura H Jacobson; Daniel Hoyer; Dominique Fehlmann; Bernhard Bettler; Klemens Kaupmann; John F Cryan
Journal:  Psychopharmacology (Berl)       Date:  2017-01-09       Impact factor: 4.530

Review 4.  The GABAβ receptor as a target for antidepressant drug action.

Authors:  Subroto Ghose; Michelle K Winter; Kenneth E McCarson; Carol A Tamminga; Salvatore J Enna
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

5.  Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents.

Authors:  G Nowak; A Partyka; A Pałucha; B Szewczyk; J M Wierońska; M Dybała; M Metz; T Librowski; W Froestl; M Papp; A Pilc
Journal:  Br J Pharmacol       Date:  2006-08-21       Impact factor: 8.739

6.  Redistribution of GABAB(1) protein and atypical GABAB responses in GABAB(2)-deficient mice.

Authors:  Martin Gassmann; Hamdy Shaban; Réjan Vigot; Gilles Sansig; Corinne Haller; Samuel Barbieri; Yann Humeau; Valérie Schuler; Matthias Müller; Bernd Kinzel; Klaus Klebs; Markus Schmutz; Wolfgang Froestl; Jakob Heid; Peter H Kelly; Clive Gentry; Anne-Lise Jaton; Herman Van der Putten; Cédric Mombereau; Lucas Lecourtier; Johannes Mosbacher; John F Cryan; Jean-Marc Fritschy; Andreas Lüthi; Klemens Kaupmann; Bernhard Bettler
Journal:  J Neurosci       Date:  2004-07-07       Impact factor: 6.167

7.  Fluoxetine partly exerts its actions through GABA: a neurochemical evidence.

Authors:  M Zafer Gören; Esra Küçükibrahimoglu; Kemal Berkman; Berna Terzioglu
Journal:  Neurochem Res       Date:  2007-05-08       Impact factor: 3.996

8.  Effects of fluoxetine on CRF and CRF1 expression in rats exposed to the learned helplessness paradigm.

Authors:  Georgina Valeria Fernández Macedo; María Laura Cladouchos; Laura Sifonios; Pablo Martín Cassanelli; Silvia Wikinski
Journal:  Psychopharmacology (Berl)       Date:  2012-09-08       Impact factor: 4.530

Review 9.  Innovative approaches for the development of antidepressant drugs: current and future strategies.

Authors:  Lee E Schechter; Robert H Ring; Chad E Beyer; Zoë A Hughes; Xavier Khawaja; Jessica E Malberg; Sharon Rosenzweig-Lipson
Journal:  NeuroRx       Date:  2005-10

Review 10.  From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes.

Authors:  Alessandro Serretti; Paola Artioli
Journal:  Psychopharmacology (Berl)       Date:  2004-03-02       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.